Amendment Flag Current Fiscal Year End Date Document Period End Date Entity [Domain] Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Filer Category Entity Registrant Name Entity Central Index Key Entity Common Stock, Shares Outstanding Document Fiscal Year Focus Document Fiscal Period Focus Legal Entity [Axis] Document Type Area of office space (in square feet) Area of Land Basis of Presentation, Liquidity and Summary of Significant Accounting Policies [Abstract] Accounts payable and accrued liabilities Total Accounts Payable and Accrued Liabilities, Current Accounts Payable and Accrued Liabilities Accounts Payable and Accrued Liabilities Disclosure [Text Block] Accounts payable Accrued expenses Accumulated depreciation and amortization Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Accumulated other comprehensive income (loss) Accumulated Other Comprehensive Income (Loss), Net of Tax Adjustments to reconcile net income (loss) attributable to BioTime, Inc. to net cash used in operating activities: Total stock-based compensation expense Allocated Share-based Compensation Expense Amortization of intangible assets Amortization of discount on related party convertible debt Amortization of Debt Discount (Premium) Antidilutive Securities [Axis] Anti-dilutive shares excluded from computation of diluted income (loss) per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities, Name [Domain] TOTAL ASSETS Assets ASSETS Assets [Abstract] CURRENT ASSETS Total current assets Assets, Current Available for sale securities Basis of Presentation, Liquidity and Summary of Significant Accounting Policies Capital lease liability, current portion Working capital Capital Capital lease, net of current and other liabilities At end of the period At beginning of the period Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Deconsolidation of cash and cash equivalents of OncoCyte Cash Divested from Deconsolidation NET CHANGE IN CASH AND CASH EQUIVALENTS: Cash and Cash Equivalents, Period Increase (Decrease) CASH AND CASH EQUIVALENTS: Cash, cash equivalents and available for sale securities Cash, Cash Equivalents, and Short-term Investments Commitments and Contingencies Commitments and contingencies (Note 13) Commitments and Contingencies [Abstract] Common shares, shares issued (in shares) Common stock, issued (in shares) Common stock, par value (in dollars per share) Common stock, shares authorized (in shares) Common stock, authorized (in shares) Common shares, no par value, 150,000 shares authorized; 110,860 shares issued and outstanding and 103,396 issued and 102,776 shares outstanding as of March 31, 2017 and December 31, 2016, respectively Common shares reserved for future issuance (in shares) Common shares, shares outstanding (in shares) Common stock, outstanding (in shares) Common Shares [Abstract] Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract] COMPREHENSIVE INCOME (LOSS) Comprehensive Income (Loss), Net of Tax, Attributable to Parent COMPREHENSIVE INCOME (LOSS) ATTRIBUTABLE TO BIOTIME, INC. COMMON SHAREHOLDERS Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Principles of consolidation Amount of convertible note Related party convertible debt, net of discount Carrying value of convertible notes Convertible Notes Payable [Member] Related party convertible debt, net of discount Cost of sales Cost of Revenue Conversion price (in dollars per share) Accrued interest is payable period Unamortized debt discount Stated interest rate Effective annual interest rate Deferred income tax expense (benefit), federal Deferred Federal Income Tax Expense (Benefit) Deferred license and subscription revenue, current portion Deferred rent liabilities, net of current portion Deferred income tax provision Deferred income tax benefit Deferred income tax provision Deferred revenues, net of current portion Deferred income tax expense (benefit), state taxes Deferred State and Local Income Tax Expense (Benefit) Deferred tax liability Deferred tax liabilities, net Deposits and other long-term assets Deposits Assets, Noncurrent Depreciation expense, including amortization of leasehold improvements Depreciation and amortization expense Stock Option Plans Stock Option Plans [Abstract] Receivables from related party Due from Related Parties, Current Receivable from affiliates, net (Note 9) Basic and diluted net income (loss) per share attributable to common shareholders Earnings Per Share, Policy [Policy Text Block] BASIC (in dollars per share) DILUTED (in dollars per share) NET INCOME (LOSS) PER COMMON SHARE: Effect of exchange rate changes on cash and cash equivalents Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] Accrued compensation Employee-related Liabilities, Current Stock Options [Member] Investment, Name [Domain] Shareholders' Equity [Abstract] Equity Component [Domain] Current assets Equity Method Investment, Summarized Financial Information, Current Assets Condensed Statements of Operations [Abstract] Condensed Balance Sheet information [Abstract] Total revenue Loss from operations Equity Method Investment, Summarized Financial Information, Income (Loss) from Continuing Operations Net loss Equity Method Investment, Summarized Financial Information, Net Income (Loss) Current liabilities Equity Method Investment, Summarized Financial Information, Current Liabilities Total liabilities and stockholders' equity Equity Method Investment, Summarized Financial Information, Liabilities and Equity Equity method ownership percentage Equity method ownership percentage Gross profit Equity Method Investment, Summarized Financial Information, Gross Profit (Loss) Total assets Equity Method Investment, Summarized Financial Information, Assets Equity Method Accounting for Common Stock of OncoCyte, at fair value [Abstract] Equity Method Accounting for Common Stock of Asterias, at fair value [Abstract] Equity Method Investments and Joint Ventures [Abstract] Equity method investment in OncoCyte, at fair value (Note 4) Noncurrent liabilities Fair value on investment Equity method investment in Asterias, at fair value (Note 5) Stockholders' equity Equity Method Investment Summarized Financial Information, Equity Noncurrent assets Equity method accounting for Asterias and OncoCyte, at fair value Unaudited results of operations and condensed balance sheet information Equity Method Investments [Table Text Block] Intangible assets, net Intangible assets, net Finite-Lived Intangible Assets, Net Accumulated amortization Finite-Lived Intangible Assets, Accumulated Amortization Intangible assets Finite-Lived Intangible Assets, Gross Intangible assets, net [Abstract] Finite-Lived Intangible Assets, Net [Abstract] Equipment, Furniture and Fixtures [Member] Furniture and Fixtures [Member] General and administrative General and Administrative Expense General and Administrative [Member] Intangible assets, net [Abstract] Gross profit Gross Profit Income Taxes [Abstract] Income Statement Location [Axis] BioTime's share of losses in equity method investment in Ascendance Biotechnology, Inc. Income Statement Location [Domain] INCOME (LOSS) BEFORE INCOME TAX BENEFIT Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Income Taxes Income Tax Disclosure [Text Block] CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) [Abstract] Accounts and grants receivable, net Increase (Decrease) in Accounts Receivable Accounts payable and accrued liabilities Receivables from affiliates, net of payables Changes in operating assets and liabilities: Restricted cash Increase (Decrease) in Restricted Cash Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Intangible assets, net Interest expense, net Common stock, outstanding (in shares) Investment Owned, Balance, Shares Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Leased area Land Subject to Ground Leases Lease Arrangement, Type [Domain] Lease Arrangement, Type [Axis] Leasehold Improvements [Member] TOTAL LIABILITIES Liabilities TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY Liabilities and Equity LIABILITIES AND SHAREHOLDERS' EQUITY Liabilities and Equity [Abstract] LONG-TERM LIABILITIES Total current liabilities Liabilities, Current CURRENT LIABILITIES Promissory notes, net of current portion Maximum [Member] Minimum [Member] Noncontrolling Interest [Table] Noncontrolling Interest [Line Items] Noncontrolling interest CASH FLOWS FROM FINANCING ACTIVITIES: Cash used in investing activities Net Cash Provided by (Used in) Investing Activities, Continuing Operations CASH FLOWS FROM OPERATING ACTIVITIES: Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities, Continuing Operations Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities, Continuing Operations CASH FLOWS FROM INVESTING ACTIVITIES: Net income (loss) attributable to BioTime, Inc. NET INCOME (LOSS) ATTRIBUTABLE TO BIOTIME, INC. Net loss allocable to non-controlling interest Net loss attributable to non-controlling interest Less: Comprehensive loss attributable to non-controlling interest Recently Issued Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Taxable gain on asset transfer Total other income/(expense), net Nonoperating Income (Expense) OTHER INCOME/(EXPENSES): Promissory notes, current portion Gain on deconsolidation Gain on deconsolidation of OncoCyte Gain on deconsolidation of OncoCyte (Note 3) OPERATING EXPENSES: Total operating expenses Operating Expenses Loss from operations Operating Income (Loss) Operating Leased Assets [Line Items] Organization and Business Overview [Abstract] Organization and Business Overview Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Other Other Noncash Income (Expense) Other comprehensive income (loss), net of tax: Available for sale investments: Unrealized gain on available-for-sale securities, net of taxes Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Net of Tax Change in foreign currency translation Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax Other income, net Other long term liabilities Other Liabilities, Noncurrent Other current liabilities Other Accrued Liabilities, Current Parent [Member] Accounts Payable and Accrued Liabilities [Abstract] Other Payments for (Proceeds from) Other Investing Activities Payments on construction in progress Payments for Capital Improvements Rent per month Payments for Rent Purchase of equipment and other assets Payments to Acquire Other Property, Plant, and Equipment Plan Name [Domain] Plan Name [Axis] Preferred shares, shares issued (in shares) Preferred stock, issued (in shares) Preferred Shares [Abstract] Preferred Stock, Number of Shares, Par Value and Other Disclosures [Abstract] Preferred stock, par value (in dollars per share) Preferred shares, shares authorized (in shares) Preferred stock, authorized (in shares) Preferred shares, shares outstanding (in shares) Preferred stock, outstanding (in shares) Preferred shares, no par value, authorized 2,000 shares; none issued and outstanding as of March 31, 2017 and December 31, 2016 Prepaid expenses and other current assets Reclassifications Proceeds from issuance of related party convertible debt Proceeds from Convertible Debt Net proceeds from sale of common shares of subsidiary Proceeds from Noncontrolling Interests Proceeds from issuance of common shares Proceeds from Issuance of Common Stock Proceeds from equity financing after discount, commission and other expenses Proceeds from related party Proceeds from exercises of stock options Proceeds from Stock Options Exercised NET INCOME (LOSS) NET INCOME (LOSS) Property, Plant and Equipment, Type [Domain] Property, plant and equipment net [Abstract] Property, plant and equipment, net [Abstract] Property, plant and equipment, net Property, Plant and Equipment [Table Text Block] Property, plant and equipment, net Property, plant and equipment, net Property, Plant and Equipment [Line Items] Property, plant and equipment Property, Plant and Equipment, Type [Axis] Property, plant and equipment, net Property, Plant and Equipment Disclosure [Text Block] Range [Axis] Range [Domain] Related Party Transactions Related Party Transaction [Line Items] Related Party Transactions [Abstract] Repayment of capital lease obligation Repayments of Long-term Capital Lease Obligations Research and development Research and Development Expense Research and Development [Member] Research and Development Expense [Member] Restricted Stock Units (RSUs) [Member] Accumulated deficit Accumulated deficit Grant income Royalties from product sales and license fees Options forfeited/cancelled (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Number of Shares Expected life Options exercised (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares Beginning of the period (in shares) End of the period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares Proceeds from sale of stock Sale of Stock, Consideration Received on Transaction Purchase price per share (in dollars per share) REVENUES: Revenue, Net [Abstract] Total revenues Revenue, Net Sale of research products Schedule of share-based compensation, employee stock purchase plan, activity Accounts payable and accrued liabilities Schedule of Accounts Payable and Accrued Liabilities [Table Text Block] Summary of stock option activity Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] Schedule of weighted average assumptions to calculate fair value of stock options Antidilutive securities excluded from computation of earnings per share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Intangible assets Schedule of Finite-Lived Intangible Assets [Table Text Block] Schedule of Operating Leased Assets [Table] Schedule of Equity Method Investments [Table] Schedule of Equity Method Investments [Line Items] Investment, Name [Axis] Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table] Property, Plant and Equipment [Table] Schedule of Related Party Transactions, by Related Party [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Stock-based compensation Options granted (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price All stock-based compensation expense [Abstract] Options exercised (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Number of RSUs Outstanding [Roll Forward] Options granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Weighted Average Exercise Price of Options [Rollforward] Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Price per share on NYSE MKT (in dollars per share) Share Price Warrants Outstanding Beginning Balance (in shares) Warrants Outstanding Ending Balance (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Risk-free interest rates Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Options forfeited/cancelled (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period Weighted-average assumptions [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract] Dividend yield Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Volatility Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Outstanding end of the period (in dollars per share) Outstanding, beginning of the period (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Outstanding, beginning of the period (in shares) Outstanding, end of the period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Number of Options Outstanding [Rollforward] Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Options forfeited/cancelled (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Equity Components [Axis] CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) [Abstract] CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (UNAUDITED) [Abstract] CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) [Abstract] Number of shares sold (in shares) Options exercised (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period SHAREHOLDERS' EQUITY Shareholders' equity Total shareholders' equity Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Shareholders' Equity Stockholders' Equity Note Disclosure [Text Block] BioTime, Inc. shareholders' equity Stockholders' Equity Attributable to Parent Subsequent Events [Abstract] Subsequent Event [Member] Subsequent Events Subsequent Event Type [Axis] Subsequent Event [Line Items] Subsequent Event [Table] Subsequent Event Type [Domain] Treasury Stock [Member] Treasury stock (in shares) Treasury stock at cost: no shares as of March 31, 2017; 620 shares as of December 31, 2016 Treasury Stock, Value Warrants [Member] Warrant [Member] Weighted average dilutive common shares used to compute diluted net income per common share (in shares) DILUTED (in shares) WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK OUTSTANDING: Weighted Average Number of Shares Outstanding, Diluted [Abstract] BASIC (in shares) Weighted Average Number of Shares Outstanding, Basic Disclosure of accounting policy pertaining to new accounting pronouncements adopted that impact the entity's financial reporting. New Accounting Pronouncements Adopted [Policy Text Block] Adoption of ASU 2016-09, Improvements to Employee Share-Based Payment Accounting Disclosure of accounting policy regarding liquidity position of the entity during the period. Liquidity [Policy Text Block] Liquidity Liquidity [Abstract] Refers to the amount of short-term, highly liquid investments that are readily convertible to amounts of cash. Cash, Cash Equivalents, Combined Value Cash and cash equivalents, available for sale securities, combined value Refers to reclassification from subscription and advertisement revenues during the period. Reclassifications From Subscription and Advertisement Revenues Reclassifications from subscription and advertisement revenues to royalties Another company which is controlled, directly or indirectly, by its parent. The usual condition for control is ownership of a majority (over 50%) of the outstanding voting stock. The power to control may also exist with a lesser percentage of ownership, for example, by contract, lease, agreement with other stockholders or by court decree. Asterias Biotherapeutics [Member] Asterias Biotherapeutics, Inc. [Member] Another company which is controlled, directly or indirectly, by its parent. The usual condition for control is ownership of a majority (over 50%) of the outstanding voting stock. The power to control may also exist with a lesser percentage of ownership, for example, by contract, lease, agreement with other stockholders or by court decree. OrthoCyte Corporation [Member] Another company which is controlled, directly or indirectly, by its parent. The usual condition for control is ownership. The power to control may also exist with a lesser percentage of ownership, for example, by contract, lease, agreement with other stockholders or by court decree. Asterias Biotherapeutics and OncoCyte [Member] Asterias Biotherapeutics and OncoCyte [Member] Refers to number of subsidiaries owned by the parent company. Number of Subsidiaries Number of subsidiaries Refers to the number of clinical stage programs on proprietary cell therapy platforms. Number of Clinical Stage Programs Number of clinical stage programs Refers to number of proprietary platform technologies having by the entity and subsidiaries. Number of Platform Technologies Number of platform technologies Refers to the number of primary sectors that targeted by the current clinical programs of the entity. Number of Primary Sectors Number of primary sectors Refers to number of common stock and warrants issued rights to purchase common shares and warrants. Issuance of Common Stock and Warrants Warrants exercised (in shares) Another company which is controlled, directly or indirectly, by its parent. The usual condition for control is ownership of a majority (over 50%) of the outstanding voting stock. The power to control may also exist with a lesser percentage of ownership, for example, by contract, lease, agreement with other stockholders or by court decree. OncoCyte Corporation [Member] OncoCyte [Member] Equity Method Accounting for Common Stock of Asterias, at fair value [Abstract] The entire disclosure for equity method accounting for common stock of Asterias, at fair value. Equity Method Accounting for Common Stock of Asterias, at fair value [Text Block] Equity Method Accounting for Common Stock of Asterias, at fair value Equity Method Accounting for Common Stock of OncoCyte, at fair value [Abstract] The entire disclosure for equity method accounting for common stock of OncoCyte, at fair value. Equity Method Accounting for Common Stock of OncoCyte, at fair value [Text Block] Equity Method Accounting for Common Stock of OncoCyte, at fair value Deconsolidation of OncoCyte and Asterias [Abstract] The entire disclosure for deconsolidation of or with a subsidiary or entity acquiring the group of assets after it has been deconsolidated or derecognized. Deconsolidation of OncoCyte and Asterias [Text Block] Deconsolidation of OncoCyte and Asterias Amount of unrealized loss on sale or disposal of equity in securities of subsidiaries or equity method investee. Unrealized Loss on Sale of Stock in Subsidiary or Equity Method Investee Unrealized loss on equity method investment A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. Share Based Compensation Arrangement By Share Based Payment Award Options Available for Grant [Roll Forward] Shares Available for Grant [Rollforward] Gross number of share options (or share units) granted during the period. Share Based Compensation Arrangement By Share Based Payment Award Options Available Grants In Period Gross Options granted (in shares) Name of stock option plan originating in 2012. Stock Option Plan Of 2012 [Member] 2012 Plan [Member] Refers to equity method investment gain (loss) fair value disclosure. Equity Method Investment Gain (Loss) Fair Value Disclosure Gain on equity method investment in OncoCyte at fair value Unrealized gain on equity method investment in OncoCyte at fair value The increase (decrease) during the reporting period reflecting grant income yet to be earned. Increase Decrease in Deferred grant income Deferred grant income Amount of contingently issuable subsidiary warrants in lieu of investor relations expenses. Contingently issuable subsidiary warrants in lieu of investor relations expenses Subsidiary shareholder expense for subsidiary warrants Amount of foreign currency remeasurement realized & unrealized gain (loss) recognized and other in the income statement. Foreign currency remeasurement (gain) or loss and other Foreign currency remeasurement (gain) or loss and other The cash outflow associated with fee paid on sale of common shares during the period. Fees paid on sale of common shares Fees paid on sale of common shares Refers to proceeds from landlord on construction in progress. Proceeds from Construction in Progress Reimbursement from landlord on construction in progress Refers to equity method investment gain (loss) fair value disclosure. Equity Method Investment Earnings (loss) Fair Value Disclosure Loss on equity method investment in Asterias at fair value Unrealized loss on equity method investment in Asterias at fair value Amount of unrealized gain (loss) on sale or disposal of equity in securities of subsidiaries or equity method investee. Unrealized Gain Loss On Sale Of Stock In Subsidiary Or Equity Method Investee Unrealized gains on equity method investment Amount of research and development expense reported by an equity method investment of the entity. Equity Method Investment Summarized Financial Information Research And Development Expense Research and development expense Amount of general and administrative expense reported by an equity method investment of the entity. Equity Method Investment Summarized Financial Information General and Administrative Expense General and administrative expense Refers to the base monthly rent as per lease agreement. Base rent Represents the number of years for which the lease can be extended. Number of years lease can be extended Number of years lease can be extended This line item represents the term to which asset leased. Lease Term Lease term Date which lease or group of leases is set to commence, in CCYY-MM-DD format. Lease Commenced date Lease commencement date This refer to base rent increase rate per year as per lease agreement. Base rent increase rate Base rent increase rate Refers to number of buildings in which rentable space is taken on lease. Number of Buildings for Lease Number of buildings for lease Refers to the lease agreement with New Alameda. New Alameda Lease [Member] Revenue from the sale of subscriptions of advertising time (such as television and radio) or space (newspaper or magazine pages). May also include advertising, marketing and promotional services rendered during the reporting period. Subscription and advertisement revenues Amount of tenant allowance due from lessor to lessee per the lease agreement to cover building improvements and or construction costs. Tenant Allowance Receivable Landlord receivable The aggregate carrying amount, as of the balance sheet date, of noncurrent liabilities related to a lease agreement. Landlord Liabilities Noncurrent Lease liability Carrying amounts as of the balance sheet of noncurrent portion of deferred license fees paid to acquire rights to use the proprietary technologies of third parties. Deferred License Fees, Noncurrent Deferred license fees Amount due from customers or clients for goods or services that have been delivered or sold in the normal course of business within one year or the normal operating cycle, if longer, net of allowance for doubtful accounts, and the amounts due under the terms of governmental, corporate, or foundation grants. Trade accounts and grants receivable net current Trade accounts and grants receivable, net Maximum aggregate offering price of shares under sales agreement. Aggregate offering price Aggregate offering price Refers to a commission payable to the seller as a percentage of gross proceeds from the sale of shares of the entity. Sales Commission, Percentage of Gross Proceeds Percentage of commission payable An investment bank and brokerage business. Cantor Fitzgerald & Co [Member] Represents the percentage of interest charged on invoices not paid when due. Interest On Unpaid Overdue Invoice Interest rate charged on unpaid and overdue invoices Refers to the price per share of the estimated fair market value feature embedded in the debt instrument. Estimated fair market value Estimated fair market value (in dollars per share) Represents the maximum number of days upon the receipt of an invoice within which the invoice must be paid, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Term Of Payment Term of payment The percentage markup of the fee for the services and usage of facilities, equipment, and supplies aforementioned which shall be paid by the entity under Shared Facilities Agreement. Percentage Of Markup Fee Allocated But Not Charged Markup rate on allocated costs Another company which is controlled, directly or indirectly, by its parent. The usual condition for control is ownership of a majority (over 50%) of the outstanding voting stock. The power to control may also exist with a lesser percentage of ownership, for example, by contract, lease, agreement with other stockholders or by court decree. Cell Cure Neurosciences, Ltd. [Member] Cell Cure Neurosciences, Ltd. [Member] Another company which is controlled, directly or indirectly, by its parent. The usual condition for control is ownership of a majority (over 50%) of the outstanding voting stock. The power to control may also exist with a lesser percentage of ownership, for example, by contract, lease, agreement with other stockholders or by court decree. Ascendance Biotechnology, Inc [Member] Ascendance Biotechnology, Inc [Member] Refers to the price per share of the estimated intrinsic value feature embedded in the debt instrument. Estimated Intrinsic Value Intrinsic value (in dollars per share) Document and Entity Information [Abstract]